excluding Genzyme) and were supported by strong performances for Plavix
® (+28.1% to euro 67 million) and Lantus
® (+50.6%) and the contribution from BMP Sunstone. Sales in Brazil increased by 16.7% to euro 386 million, due to strong performance from generics and the contribution from Genzyme. Sales in Russia were euro 184 million, up 7.7%. Sales in Eastern Europe were euro 687 million, up 4.6% (-1.0% excluding Genzyme) and were impacted by a decrease in sales in Turkey due to generic competition for Taxotere
®. First-half sales in Emerging Markets were euro 4,919 million, an increase of 10.5% excluding Genzyme and A/H1N1 vaccines (euro 361 million, primarily in Latin America and Middle East), or an increase of 2.2% excluding Genzyme.
Japan recorded net sales of euro 699 million in the second quarter, an increase of 26.6% (+14.3% excluding Genzyme), sustained by Plavix® (up 21.7% to euro 162 million), Allegra® (22.8% to euro 88 million) and vaccines (+63.9%) and the contribution from Genzyme. First-half sales in Japan were euro 1,368 million, (up 20.4%, or up 14.0 % excluding Genzyme) of which euro 301 million were generated by Plavix® (+24.6%) and euro 274 million by Allegra® (+34.1%), respectively.
Second quarter net sales in the U.S. reached euro 2,416 million, an increase of 3.3%, reflecting the acquisition of Genzyme (sales of euro 379 million). Excluding Genzyme, sales in the U.S. were down 12.9%. This decrease reflected the impact of generics of Taxotere®, Lovenox® and Ambien®CR, which was partially offset by sales of Allegra® OTC, Jevtana® and Multaq® and strong growth of Lantus®. First-half sales in the U.S. were euro 4,580 million (up 0.3 % and down 8.6% excluding Genzyme).
Western Europe achieved second-quarter net sales of euro 2,380 million, an increase of 0.9%. This figure include
'/>"/>
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Related medicine technology :1.
New Senior Executives Appointed at Sanofi:2.
VR Business Sales, Mergers & Acquisitions Charlotte Completes Sale of Penrod Medical Equipment3.
Global Medical Devices Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Marketing Spend and Sales Strategies4.
TPI Ships Macrolide API Samples for International Sales Standard Testing5.
Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer6.
Burlington Medical Supplies Reorganizes Sales and Marketing Operations7.
HASCO Medical Inc. Names Mike Dumais the Vice President of Sales for Southern Medical and Mobility8.
GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives9.
With Launch of New ActiveHome Monitoring System, ActiveCare Announces New Head of Sales and Marketing10.
TPI Signs Macrolide API International Sales and Marketing Agreement11.
CellerateRX TV Commercials Begin Airing on Fox News Network via Geraldo at Large and Fox News Sunday Programs, Expanding the Direct-To-Consumer Sales Program